ECSP19008417A - Anticuerpos con inmunogenicidad baja y usos de estos - Google Patents

Anticuerpos con inmunogenicidad baja y usos de estos

Info

Publication number
ECSP19008417A
ECSP19008417A ECSENADI20198417A ECDI201908417A ECSP19008417A EC SP19008417 A ECSP19008417 A EC SP19008417A EC SENADI20198417 A ECSENADI20198417 A EC SENADI20198417A EC DI201908417 A ECDI201908417 A EC DI201908417A EC SP19008417 A ECSP19008417 A EC SP19008417A
Authority
EC
Ecuador
Prior art keywords
antibodies
low immunogenicity
antigen
methods
binding fragments
Prior art date
Application number
ECSENADI20198417A
Other languages
English (en)
Inventor
Kandasamy Hariharan
Lawrence Dearth
Jeffrey Johnson
Haralambos Hadjivassiliou
Jeonghoon Sun
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ECSP19008417A publication Critical patent/ECSP19008417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan anticuerpos y fragmentos de unión al antígeno de estos con inmunogenicidad baja o nula en seres humanos y opcionalmente con características de fabricación deseables. También se proporcionan composiciones que comprenden dichos anticuerpos o fragmentos de unión al antígeno, métodos para utilizar dichos anticuerpos, y métodos para elaborar dichos anticuerpos.
ECSENADI20198417A 2016-07-06 2019-02-05 Anticuerpos con inmunogenicidad baja y usos de estos ECSP19008417A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
ECSP19008417A true ECSP19008417A (es) 2019-02-28

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20198417A ECSP19008417A (es) 2016-07-06 2019-02-05 Anticuerpos con inmunogenicidad baja y usos de estos

Country Status (19)

Country Link
US (1) US11427632B2 (es)
EP (1) EP3481862A4 (es)
JP (1) JP7120989B2 (es)
KR (1) KR20190035737A (es)
CN (1) CN109689684B (es)
AR (1) AR108975A1 (es)
AU (1) AU2017292752B2 (es)
BR (1) BR112019000166A2 (es)
CA (1) CA3029977A1 (es)
CL (1) CL2019000019A1 (es)
CO (1) CO2019001112A2 (es)
EA (1) EA201990218A1 (es)
EC (1) ECSP19008417A (es)
IL (1) IL264009A (es)
MX (1) MX2019000172A (es)
SG (1) SG11201811788SA (es)
TW (1) TW201811824A (es)
WO (1) WO2018009499A1 (es)
ZA (1) ZA201900070B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
JP2023545983A (ja) 2020-10-07 2023-11-01 セルジーン コーポレイション リンパ系悪性腫瘍状態の二重特異性抗体治療
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
CL2007000851A1 (es) 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2011075861A1 (en) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
EA034778B1 (ru) * 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
DK2890402T3 (da) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
MX2017006485A (es) 2014-11-18 2018-03-23 Janssen Pharmaceutica Nv Anticuerpos anti-cd47, metodos y usos.
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
HK1257309A1 (zh) * 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法

Also Published As

Publication number Publication date
MX2019000172A (es) 2019-09-26
JP2019524087A (ja) 2019-09-05
US20190241654A1 (en) 2019-08-08
IL264009A (en) 2019-01-31
AR108975A1 (es) 2018-10-17
AU2017292752B2 (en) 2023-07-27
EP3481862A4 (en) 2020-08-12
CN109689684B (zh) 2022-09-23
ZA201900070B (en) 2023-08-30
BR112019000166A2 (pt) 2019-10-01
JP7120989B2 (ja) 2022-08-17
WO2018009499A1 (en) 2018-01-11
CO2019001112A2 (es) 2019-02-19
SG11201811788SA (en) 2019-01-30
TW201811824A (zh) 2018-04-01
EP3481862A1 (en) 2019-05-15
CA3029977A1 (en) 2018-01-11
CL2019000019A1 (es) 2019-06-28
US11427632B2 (en) 2022-08-30
EA201990218A1 (ru) 2019-07-31
AU2017292752A1 (en) 2019-01-24
KR20190035737A (ko) 2019-04-03
CN109689684A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
MX391249B (es) Anticuerpos anti-muc16 y sus usos.
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20180267A1 (es) Composiciones que comprenden cepas bacterianas
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX378368B (es) Receptores de antigeno y usos de los mismos.
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
MX385109B (es) Formulaciones de anticuerpos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos